Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease (ApoD)
Recruitment status was: Enrolling by invitation
In Italy affected people are 200,000 and every year Parkinson new cases are 10,000. Aging is the principle risk factor of Parkinson with the possibility of its development doubling every five years after 65. Because of the increase of the social longevity and aging as the main risk factor, there are many repercussions on the health system (hospital stays and pharmaceutical costs) as on the social system (assistance- related problems). Parkinson's disease exerts an extremely negative impact on life's quality of the patient. In fact, because of Parkinson symptoms (tremor, dribble, etc), patient's social life will be reduced with the consequent development of the depression. Consequently, the early detection and treatment of Parkinson's is necessary.
To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative stress-inflammation vicious cycle seems most promising candidate for diagnosis.
|Study Design:||Observational Model: Cohort|
|Official Title:||Detection of Apolipoprotein D (ApoD) in Human Serum as Marker of Parkinson's Disease|
- Detection of Apolipoprotein D [ Time Frame: Baseline ]Apolipoprotein D (apoD)concentration in human serum as a potential marker for Parkinson's disease (PD)
Biospecimen Retention: Samples With DNA
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||November 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
Healthy Subjects aged 20-40
Healthy Subjects aged 40-65
Healthy Subjects aged more than 65
Patients at Stage I, H&Y classification
Patients at Stage II, H&Y classification
Patients at Stage more than III, H&Y classification
Total participants: n=180.
Study Part 1:
Health persons: n=90; Groups of health persons: n=3; Subjects per group: n=30.
Study Part 2:
Patients: n=90; Groups of patients: n=3; Subjects per group: n=30.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01467960
|Privatklinik Villa Melitta|
|Bozen, Südtirol, Italy, 39100|
|Study Director:||Andreas Waldner, MD||Privatklinik Villa Melitta|
|Principal Investigator:||Sarah Dassati, BSc||Privatklinik Villa Melitta|